Causes of secondary non-alcoholic fatty liver disease in non-obese children below 10 years

Engy A Mogahed1, Al-Hussien A Sayed2, Sara E Khalifa3

  • 1Pediatrics Department, Kasr Alainy Medical School, Cairo University, 2B Sama City, Katamya, Cairo, 11439, Egypt. engy.mogahed@kasralainy.edu.eg.

Insights

In Egyptian children under 10, secondary causes like Glycogen Storage Disease (GSD) and Hepatitis C Virus (HCV) are common in fatty liver disease. Higher steatosis degrees correlated with more severe liver fibrosis.

Area of Science:

  • Pediatric Hepatology
  • Gastroenterology
  • Liver Pathology

Background:

  • Primary non-alcoholic fatty liver disease (NAFLD) is uncommon in children younger than 10 years.
  • Secondary etiologies of NAFLD should be investigated in pediatric patients lacking typical risk factors.

Purpose of the Study:

  • To identify the causes and histopathological characteristics of NAFLD in Egyptian children under 10 years.
  • To assess the prevalence of non-alcoholic steatohepatitis (NASH) using the NAFLD activity score.

Main Methods:

  • Retrospective analysis of 66 children under 10 with biopsy-proven fatty liver over six years.
  • Histopathological examination and NAFLD activity score for NASH detection.
  • Evaluation of transaminase levels and common causes of liver steatosis.

Main Results:

  • Glycogen storage disease (GSD) was the most frequent cause (33.3%), followed by Hepatitis C Virus (HCV) (10.6%) and Chanarin-Dorfman syndrome (CDS) (9.1%).
  • Secondary causes of NAFLD were more prevalent in this pediatric cohort.
  • Severe steatosis (39.4%) was observed in all cases, with higher degrees in younger children. Significant correlation found between steatosis and fibrosis severity (P=0.01).

Conclusions:

  • GSD, HCV, and CDS are primary drivers of secondary NAFLD in young Egyptian children.
  • Younger children exhibit higher degrees of steatosis, which is directly linked to increased liver fibrosis.
  • The study highlights the importance of investigating secondary causes in pediatric fatty liver disease.

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.6K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
152
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
430
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
133